Paula Runyon
Psychiatric/Mental Health · Hazard, KYNPI 1952621807
Payments from drug & device makers
Across 344 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$885
- AbbVie$784
- Johnson & Johnson$722
- Axsome Therapeutics, Inc.$522
- Alkermes, Inc.$446
- Otsuka America Pharmaceutical, Inc.$402
- plus $3K from 29 others
What the payments were for
- Consulting fees$1152%
- Food & beverage$6,13297%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$689
- Auvelity$250
- SPRAVATO$115
- Mavyret$111
- INVEGA SUSTENNA$107
How this compares
$6,294 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 114 | $112,943 |
| IngrezzaValbenazine Tosylate | 11 | $83,230 |
| RexultiBrexpiprazole | 19 | $33,840 |
| TrintellixVortioxetine Hydrobromide | 36 | $29,215 |
| VraylarCariprazine Hcl | 12 | $17,735 |
| JanuviaSitagliptin Phosphate | 16 | $13,451 |
| Asenapine Maleate | 14 | $5,087 |
| Aripiprazole | 37 | $2,559 |
| Lisdexamfetamine Dimesylate | 12 | $2,527 |
| Lamotrigine | 113 | $707 |
| Prazosin Hcl | 41 | $505 |
| Olanzapine | 19 | $495 |
| Buspirone Hcl | 60 | $461 |
| Clonazepam | 69 | $428 |
| Ziprasidone Hcl | 23 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $722 | $112,943114 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $16 | $83,23011 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $402 | $33,84019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $324 | $29,21536 claims |
| AbbVieVraylar | $784 | $17,73512 claims |
| MerckJanuvia | $14 | $13,45116 claims |
| Lilly USA, LLCOlanzapine | $81 | $49519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Hazard
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.